GRASP cerebrospinal fluid levels of total tau protein (t-tau) (alzheimers disease subjects)
PheWAS abnormal results of function studies, acquired absence of breast, acute prostatitis, adverse effects of opiates and related narcotics in therapeutic use, anemia of chronic disease, anticoagulants causing adverse effects, astigmatism, benign neoplasm of bone and articular cartilage, benign neoplasm of breast, benign neoplasm of other endocrine glands, benign neoplasm of unspecified sites, bronchitis, cerebral edema and compression of brain, cervicocranial/cervicobrachial syndrome, chorioretinal scars, circulatory disease nec, disorders of lipoid metabolism, disorders of penis, disorders of the globe, disturbance of salivary secretion, duodenal ulcer, elevated levels of transaminase or lactic acid dehydrogenase, gastritis and duodenitis, hemorrhage from gastrointestinal ulcer, hx of malignant neoplasm of oral cavity and pharynx, hypercholesterolemia, hyperlipidemia, inflammatory disease of breast, injuries to the nervous system, lipoid metabolism disorder nos, mammographic microcalcification, mechanical complications of cardiac/vascular device, implant, and graft, memory loss, neuralgia, neuritis, and radiculitis nos, nontoxic multinodular goiter, open wound of lip and mouth, other conditions of brain, pagets disease of bone, peptic ulcer, peptic ulcers, pericarditis, poisoning by agents primarily affecting blood constituents, postinflammatory pulmonary fibrosis, progressive myopia, prostatitis, sepsis, sinoatrial node dysfunction, symptoms involving respiratory system, type 2 diabetic peripheral circulatory disorders, viral hepatitis